PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32862368-0	2020	INNO-406 inhibits the growth of chronic myeloid leukemia and promotes its apoptosis via targeting PTEN.	bafetinib	0-8	phosphatase and tensin homolog	Homo sapiens	98-102
32862368-9	2020	Rescue experiment revealed that PTEN knockdown reversed the effect of INNO-406 which indicated the correlation between INNO-406 and PTEN.	bafetinib	70-78	phosphatase and tensin homolog	Homo sapiens	32-36
32862368-9	2020	Rescue experiment revealed that PTEN knockdown reversed the effect of INNO-406 which indicated the correlation between INNO-406 and PTEN.	bafetinib	70-78	phosphatase and tensin homolog	Homo sapiens	132-136
32862368-11	2020	In vivo study further confirmed that INNO-406 inhibited the growth of CML cells by targeting PTEN.	bafetinib	37-45	phosphatase and tensin homolog	Homo sapiens	93-97
31672514-9	2020	Quercetin (200 muM) and Lyn inhibitors (Bafetinib, 10 muM) inhibit the activity of Lyn kinase, and quercetin can reduce the activation of Lyn kinase by Lyn agonist (Tolimidone, 10 muM).	bafetinib	40-49	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	24-27
31672514-9	2020	Quercetin (200 muM) and Lyn inhibitors (Bafetinib, 10 muM) inhibit the activity of Lyn kinase, and quercetin can reduce the activation of Lyn kinase by Lyn agonist (Tolimidone, 10 muM).	bafetinib	40-49	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	83-86
31672514-9	2020	Quercetin (200 muM) and Lyn inhibitors (Bafetinib, 10 muM) inhibit the activity of Lyn kinase, and quercetin can reduce the activation of Lyn kinase by Lyn agonist (Tolimidone, 10 muM).	bafetinib	40-49	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	83-86
31672514-9	2020	Quercetin (200 muM) and Lyn inhibitors (Bafetinib, 10 muM) inhibit the activity of Lyn kinase, and quercetin can reduce the activation of Lyn kinase by Lyn agonist (Tolimidone, 10 muM).	bafetinib	40-49	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	83-86
31641354-3	2019	Methods: A retrospective study carried out over a 10-year period, using clinical and molecular data, with PCR analysis and reverse hybridization (INNO-LIPA kit), in anal cancers.	bafetinib	146-150	lipase A, lysosomal acid type	Homo sapiens	151-155
30854129-8	2019	Additionally, we investigated the effects of Lyn inhibitor Bafetinib on melanoma cells and the results were consistent with Lyn knockdown.	bafetinib	59-68	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	45-48
29717260-6	2018	One such compound, bafetinib, a second generation BCR/ABL inhibitor, reduced phosphorylation of ERK and when combined with trametinib, both in vitro and in vivo, reduced growth of vemurafenib resistant melanoma cells.	bafetinib	19-28	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	50-57
29717260-6	2018	One such compound, bafetinib, a second generation BCR/ABL inhibitor, reduced phosphorylation of ERK and when combined with trametinib, both in vitro and in vivo, reduced growth of vemurafenib resistant melanoma cells.	bafetinib	19-28	mitogen-activated protein kinase 1	Homo sapiens	96-99
29615437-5	2018	Human AO substrates identified contained unsubstituted diazanaphthalene moieties (A77-01, INCB 28060, ML-347, LDN-193189, and SB-525334), 4-aminoquinazoline cores (lapatinib, lapatinib M1, and CL-387785), and terminal pyridine and pyrimidine groups (imatinib, bafetinib, and AMG 900).	bafetinib	260-269	aldehyde oxidase 1	Homo sapiens	6-8
26479578-6	2016	Baustinib, Nilotinib, Dasatinib, Ponatinib, Bafetinib, etc., which can able to combat against mutated domain of ABL tyrosine kinase protein.	bafetinib	44-53	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	112-115
27157787-0	2016	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.	bafetinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	88-93
27157787-0	2016	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.	bafetinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	98-103
27157787-2	2016	Discovered by structure-based virtual screening algorithms, bafetinib, a Bcr-Abl/Lyn tyrosine kinase inhibitor, was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation.	bafetinib	60-69	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	73-80
27157787-2	2016	Discovered by structure-based virtual screening algorithms, bafetinib, a Bcr-Abl/Lyn tyrosine kinase inhibitor, was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation.	bafetinib	60-69	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	81-84
27157787-2	2016	Discovered by structure-based virtual screening algorithms, bafetinib, a Bcr-Abl/Lyn tyrosine kinase inhibitor, was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation.	bafetinib	60-69	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
27157787-2	2016	Discovered by structure-based virtual screening algorithms, bafetinib, a Bcr-Abl/Lyn tyrosine kinase inhibitor, was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation.	bafetinib	60-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	168-173
27157787-3	2016	Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates and increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [(3)H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [(3)H]-mitoxantrone in ABCG2 overexpressing cells, respectively.	bafetinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	35-40
27157787-3	2016	Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates and increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [(3)H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [(3)H]-mitoxantrone in ABCG2 overexpressing cells, respectively.	bafetinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	45-50
27157787-3	2016	Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates and increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [(3)H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [(3)H]-mitoxantrone in ABCG2 overexpressing cells, respectively.	bafetinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	223-228
27157787-3	2016	Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates and increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [(3)H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [(3)H]-mitoxantrone in ABCG2 overexpressing cells, respectively.	bafetinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	291-296
27157787-4	2016	Bafetinib stimulated ABCB1 ATPase activities while inhibited ABCG2 ATPase activities.	bafetinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
27157787-4	2016	Bafetinib stimulated ABCB1 ATPase activities while inhibited ABCG2 ATPase activities.	bafetinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	61-66
27157787-6	2016	Overall, our study indicated that bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters.	bafetinib	34-43	ATP binding cassette subfamily B member 1	Homo sapiens	53-58
27157787-6	2016	Overall, our study indicated that bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters.	bafetinib	34-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	64-69
26458439-6	2015	Four second-generation ATP competitive ABL TKIs, i.e., dasatinib, nilotinib, bosutinib and bafetinib, have been developed.	bafetinib	91-100	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	39-42
25823815-8	2015	The Lyn-selective kinase inhibitor, Bafetinib (INNO-406), acts to reduce Claudin-2 expression and suppress breast cancer liver metastasis.	bafetinib	36-45	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	4-7
25823815-8	2015	The Lyn-selective kinase inhibitor, Bafetinib (INNO-406), acts to reduce Claudin-2 expression and suppress breast cancer liver metastasis.	bafetinib	36-45	claudin 2	Homo sapiens	73-82
25823815-8	2015	The Lyn-selective kinase inhibitor, Bafetinib (INNO-406), acts to reduce Claudin-2 expression and suppress breast cancer liver metastasis.	bafetinib	47-55	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	4-7
25823815-8	2015	The Lyn-selective kinase inhibitor, Bafetinib (INNO-406), acts to reduce Claudin-2 expression and suppress breast cancer liver metastasis.	bafetinib	47-55	claudin 2	Homo sapiens	73-82
24779362-0	2014	The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.	bafetinib	30-39	F2R like trypsin receptor 1	Homo sapiens	49-53
24779362-0	2014	The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.	bafetinib	30-39	transient receptor potential cation channel subfamily V member 4	Homo sapiens	76-81
24779362-9	2014	Functional expression of TRPV4 channels caused a sustained increase of [Ca(2+) ]i , inhibited by HC067047, bafetinib and wortmannin; but not by thapsigargin, UBO-QIC, dasatinib or LY294002.	bafetinib	107-116	transient receptor potential cation channel subfamily V member 4	Homo sapiens	25-30
24779362-10	2014	Bafetinib but not dasatinib inhibited PAR2-induced mechanical hyperalgesia in vivo.	bafetinib	0-9	F2R like trypsin receptor 1	Homo sapiens	38-42
24779362-12	2014	The ability of a tyrosine kinase inhibitor to diminish PAR2-induced activation of TRPV4 channels and consequent mechanical hyperalgesia identifies bafetinib (which is in development in oncology) as a potential novel analgesic therapy.	bafetinib	147-156	F2R like trypsin receptor 1	Homo sapiens	55-59
24779362-12	2014	The ability of a tyrosine kinase inhibitor to diminish PAR2-induced activation of TRPV4 channels and consequent mechanical hyperalgesia identifies bafetinib (which is in development in oncology) as a potential novel analgesic therapy.	bafetinib	147-156	transient receptor potential cation channel subfamily V member 4	Homo sapiens	82-87
24258348-4	2014	To overcome this resistance, four second-generation ATP competitive ABL TKIs, dasatinib, nilotinib, bosutinib and bafetinib, have been developed.	bafetinib	114-123	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	68-71
24130846-4	2013	Here, we applied an integrated experimental and computational approach that allowed us to estimate the differential impact of the bcr-abl inhibitors nilotinib, dasatinib, Bosutinib and Bafetinib.	bafetinib	185-194	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	130-137
23747655-3	2013	Bafetinib, a specific Abl/Lyn tyrosine kinase inhibitor has shown a potent antiproliferative activity in leukemic cells, but its effects on eosinophils have not been reported.	bafetinib	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	22-25
23747655-3	2013	Bafetinib, a specific Abl/Lyn tyrosine kinase inhibitor has shown a potent antiproliferative activity in leukemic cells, but its effects on eosinophils have not been reported.	bafetinib	0-9	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	26-29
23747655-7	2013	Bafetinib inhibited the release of EPO induced by fMLF with higher potency than genistein and tyrphostin (-log IC50=7.24 +- 0.09 M; 5.36 +- 0.28 M; and 5.37 +- 0.19 M, respectively), and nearly suppressed LTC4, ECP and chemotaxis.	bafetinib	0-9	erythropoietin	Homo sapiens	35-38
23747655-10	2013	The activation of Lyn tyrosine kinase, p-ERK1/2 and p-38 induced by fMLF was suppressed by bafetinib and attenuated by genistein and tyrphostin.	bafetinib	91-100	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	18-21
23747655-10	2013	The activation of Lyn tyrosine kinase, p-ERK1/2 and p-38 induced by fMLF was suppressed by bafetinib and attenuated by genistein and tyrphostin.	bafetinib	91-100	mitogen-activated protein kinase 14	Homo sapiens	52-56
23787070-4	2013	Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase.	bafetinib	75-84	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	149-156
23787070-4	2013	Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase.	bafetinib	86-94	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	149-156
23380277-0	2013	A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.	bafetinib	37-46	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	73-80
23380277-0	2013	A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.	bafetinib	37-46	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	81-84
21154127-0	2010	Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.	bafetinib	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	18-25
21154127-0	2010	Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.	bafetinib	0-9	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	26-29
21154127-1	2010	Bafetinib (NS-187, INNO-406) is a second-generation tyrosine kinase inhibitor in development by CytRx under license from Nippon Shinyaku for treating Bcr-Abl+ leukemia"s, including chronic myelogenous leukemia (CML) and Philadelphia+ acute lymphoblastic leukemia.	bafetinib	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	150-157
21154127-1	2010	Bafetinib (NS-187, INNO-406) is a second-generation tyrosine kinase inhibitor in development by CytRx under license from Nippon Shinyaku for treating Bcr-Abl+ leukemia"s, including chronic myelogenous leukemia (CML) and Philadelphia+ acute lymphoblastic leukemia.	bafetinib	11-17	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	150-157
21154127-3	2010	Besides Abl, bafetinib targets the Src family kinase Lyn, which has been associated with resistance to imatinib in CML.	bafetinib	13-22	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	53-56
21154127-5	2010	Bafetinib inhibits 12 of the 13 most frequent imatinib-resistant Bcr-Abl point mutations, but not a Thr315Ile mutation.	bafetinib	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	65-72
21154127-6	2010	A small fraction of bafetinib crosses the blood-brain barrier, reaching brain concentrations adequate for suppression of Bcr-Abl+ cells.	bafetinib	20-29	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	121-128
21124949-5	2010	We apply this procedure to the target profile of the second-generation BCR-ABL inhibitor bafetinib which is in development for the treatment of imatinib-resistant chronic myeloid leukemia.	bafetinib	89-98	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	71-78
20597967-8	2010	For such patients, novel multikinase inhibitors such as nilotinib, dasatinib, bosutinib or bafetinib, which block the kinase activity of various BCR/ABL1 mutants, have been developed and reportedly exert antileukaemic effects in drug-resistant cells.	bafetinib	91-100	BCR activator of RhoGEF and GTPase	Homo sapiens	145-148
20597967-8	2010	For such patients, novel multikinase inhibitors such as nilotinib, dasatinib, bosutinib or bafetinib, which block the kinase activity of various BCR/ABL1 mutants, have been developed and reportedly exert antileukaemic effects in drug-resistant cells.	bafetinib	91-100	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	149-153
20685234-0	2010	KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).	bafetinib	80-89	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	0-3
20685234-6	2010	In canines, growth-inhibitory effects of INNO-406 were seen in C2 cells (IC(50): 50-100 nM) exhibiting a KIT exon 11 internal tandem-duplication and in primary neoplastic MC harboring wild-type exon 11, whereas no effects were seen in MC exhibiting a polymorphism at amino acid 581 in exon 11.	bafetinib	41-49	KIT proto-oncogene, receptor tyrosine kinase	Canis lupus familiaris	105-108
20310049-0	2010	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.	bafetinib	17-25	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	34-37
20310049-0	2010	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.	bafetinib	17-25	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	38-41
19890374-0	2010	A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.	bafetinib	74-82	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	49-56
19890374-3	2010	The second-generation BCR-ABL inhibitor INNO-406 is known to inhibit most BCR-ABL mutants and LYN efficiently.	bafetinib	40-48	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	22-29
19890374-3	2010	The second-generation BCR-ABL inhibitor INNO-406 is known to inhibit most BCR-ABL mutants and LYN efficiently.	bafetinib	40-48	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	74-81
19890374-3	2010	The second-generation BCR-ABL inhibitor INNO-406 is known to inhibit most BCR-ABL mutants and LYN efficiently.	bafetinib	40-48	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	94-97
20007109-4	2009	Although the resistance conferred by most BCR-ABL1 mutations can be overcome with the use of second-generation TKIs such as nilotinib, dasastinib, bosutinib, or bafetinib, the T315I mutation, which represents a common resistance pathway in CML, remains unassailable to TKI therapy.	bafetinib	161-170	BCR activator of RhoGEF and GTPase	Homo sapiens	42-50
18759691-4	2008	In order to override this resistance, several second generation ATP-competitive Abl TKIs including dasatinib, nilotinib, bosutinib and INNO-406 have been developed.	bafetinib	135-143	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	80-83
18338755-11	2008	The new dual Abl/Lyn inhibitor INNO-406 (formerly NS-187) was slightly more potent than nilotinib in inhibiting the growth of all 3 cell lines.	bafetinib	31-39	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	13-16
18338755-11	2008	The new dual Abl/Lyn inhibitor INNO-406 (formerly NS-187) was slightly more potent than nilotinib in inhibiting the growth of all 3 cell lines.	bafetinib	31-39	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	17-20
18338755-11	2008	The new dual Abl/Lyn inhibitor INNO-406 (formerly NS-187) was slightly more potent than nilotinib in inhibiting the growth of all 3 cell lines.	bafetinib	50-56	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	13-16
18338755-11	2008	The new dual Abl/Lyn inhibitor INNO-406 (formerly NS-187) was slightly more potent than nilotinib in inhibiting the growth of all 3 cell lines.	bafetinib	50-56	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	17-20
18191450-4	2008	INNO-406 had an intermediate affinity for BCR-ABL between that of dasatinib and nilotinib, and inhibited only SFKs LCK and LYN among SFKs.	bafetinib	0-8	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	42-49
18191450-4	2008	INNO-406 had an intermediate affinity for BCR-ABL between that of dasatinib and nilotinib, and inhibited only SFKs LCK and LYN among SFKs.	bafetinib	0-8	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	115-118
18191450-4	2008	INNO-406 had an intermediate affinity for BCR-ABL between that of dasatinib and nilotinib, and inhibited only SFKs LCK and LYN among SFKs.	bafetinib	0-8	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	123-126
18202009-3	2008	We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.	bafetinib	57-65	C-X-C motif chemokine receptor 4	Homo sapiens	79-84
19662183-0	2007	NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.	bafetinib	0-6	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	21-28
19662183-0	2007	NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.	bafetinib	0-6	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	29-32
19662183-7	2007	Our work has led to the development of NS-187 (INNO-406), a novel Abl/Lyn dual tyrosine kinase inhibitor with clinical prospects.	bafetinib	39-45	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	66-69
19662183-7	2007	Our work has led to the development of NS-187 (INNO-406), a novel Abl/Lyn dual tyrosine kinase inhibitor with clinical prospects.	bafetinib	39-45	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	70-73
17517053-0	2007	Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.	bafetinib	104-112	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	52-55
17517053-1	2007	The activity of the novel tyrosine kinase inhibitor INNO-406 against human cells with mutated KIT was investigated.	bafetinib	52-60	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	94-97
17301549-4	2007	Quite recently we successfully developed the novel Bcr-Abl/Lyn dual inhibitor INNO-406 (NS-187) which shows unique profile to overcome this resistance.	bafetinib	78-86	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	51-58
17301549-4	2007	Quite recently we successfully developed the novel Bcr-Abl/Lyn dual inhibitor INNO-406 (NS-187) which shows unique profile to overcome this resistance.	bafetinib	78-86	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	59-62
17301549-4	2007	Quite recently we successfully developed the novel Bcr-Abl/Lyn dual inhibitor INNO-406 (NS-187) which shows unique profile to overcome this resistance.	bafetinib	88-94	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	51-58
17301549-4	2007	Quite recently we successfully developed the novel Bcr-Abl/Lyn dual inhibitor INNO-406 (NS-187) which shows unique profile to overcome this resistance.	bafetinib	88-94	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	59-62
16954504-0	2007	INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.	bafetinib	0-8	LYN proto-oncogene, Src family tyrosine kinase	Mus musculus	26-29
16546254-0	2006	In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.	bafetinib	36-42	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	51-58
16546254-0	2006	In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.	bafetinib	36-42	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	59-62
16546254-0	2006	In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.	bafetinib	36-42	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	55-58
16546254-3	2006	NS-187 inhibited both Tyr393-phosphorylated and Tyr393-unphosphorylated Abl, resulting in significant in vitro growth inhibition of cells expressing six of seven mutated Bcr-Abl kinases, though not T315I.	bafetinib	0-6	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	72-75
16546254-3	2006	NS-187 inhibited both Tyr393-phosphorylated and Tyr393-unphosphorylated Abl, resulting in significant in vitro growth inhibition of cells expressing six of seven mutated Bcr-Abl kinases, though not T315I.	bafetinib	0-6	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	170-177
18221045-4	2006	To override resistance, several second generation ATP competitive Abl kinase inhibitors such as dasatinib, nilotinib and INNO-406 have been developed.	bafetinib	121-129	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	66-69
16332440-3	2006	One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia.	bafetinib	14-20	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	56-63
16105974-0	2005	NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.	bafetinib	0-6	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	36-43
16105974-0	2005	NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.	bafetinib	0-6	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	44-47
16105974-3	2005	We have identified a specific dual Abl-Lyn inhibitor, NS-187 (elsewhere described as CNS-9), which is 25 to 55 times more potent than imatinib in vitro.	bafetinib	54-60	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	35-38
16105974-3	2005	We have identified a specific dual Abl-Lyn inhibitor, NS-187 (elsewhere described as CNS-9), which is 25 to 55 times more potent than imatinib in vitro.	bafetinib	54-60	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	39-42
16105974-6	2005	NS-187 also inhibits Lyn without affecting the phosphorylation of Src, Blk, or Yes.	bafetinib	0-6	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	21-24
12911295-0	2003	Effect of hydroxylation and N187-linked glycosylation on molecular and functional properties of recombinant human surfactant protein A.	bafetinib	28-32	surfactant protein A1	Homo sapiens	114-134
33691171-7	2021	EGFR expression was negatively associated with drug sensitivity of Pipamperone, Tamoxifen, Bafetinib and positively related to drug sensitivity of Dasatinib and Staurosporine.	bafetinib	91-100	epidermal growth factor receptor	Homo sapiens	0-4